Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review.
Post transplant lymphoproliferative disorders (PTLD) complicates the course of 0.3 to 3% of renal transplant patients receiving immunosuppression. Epstein-Barr virus (EBV) related non-Hodgkin's lymphomas of B-cell type is more common than those of T-cell origin. CD30 positive Anaplastic Large Cell Lymphoma (ALCL) is a Non-Hodgkin's lymphoma (B or T cell type) that accounts for a small percentage of PTLD's. ALCL of T-cell type are a spectrum of disease ranging from primary cutaneous to systemic nodal ALCL. The systemic nodal ALCL is further subdivided into anaplastic lymphoma kinase-1 (ALK-1) positive or negative. ALK-1 protein is a gene fusion product of translocation (2;5) and carries prognostic implications. We present an unusual manifestation of ALK-1 negative CD30 positive ALCL in a post renal transplant patient in FNA cytology with all supportive adjuvant studies and differential diagnoses and review the cytology literature on this topic.
Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA. indra.balachandran@acphs.edu
Indra
I
Balachandran
Joe W
JW
Walker
Jerry
J
Broman
D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D044963:Biopsy, Fine-Needle; D002277:Carcinoma / Q000175:diagnosis; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis*; D016030:Kidney Transplantation / Q000009:adverse effects*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000737:chemistry / Q000209:etiology / Q000276:immunology / Q000473:pathology*; D008297:Male; D008479:Mediastinal Neoplasms / Q000737:chemistry / Q000209:etiology / Q000276:immunology / Q000473:pathology*; D008545:Melanoma / Q000175:diagnosis; D011183:Postoperative Complications; D011241:Prednisone / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000032:analysis*; D020794:Receptor Protein-Tyrosine Kinases; D012074:Remission Induction; D018239:Seminoma / Q000175:diagnosis / Q000556:secondary; D013736:Testicular Neoplasms / Q000175:diagnosis; D014750:Vincristine / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D011241:Prednisone